<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008358</url>
  </required_header>
  <id_info>
    <org_study_id>CT-2007-01</org_study_id>
    <secondary_id>EudraCT number 2008-001177-15</secondary_id>
    <nct_id>NCT01008358</nct_id>
  </id_info>
  <brief_title>Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>Phase II Trial of Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CP-675,206 (tremelimumab) is a fully humanized monoclonal antibody that binds to activated T&#xD;
      lymphocytes and by enhancing their activation may produce a stimulation of the immune&#xD;
      response against tumoral or viral antigens. In this clinical trial, the ability of&#xD;
      tremelimumab to produce tumor responses among hepatitis C virus-infected patients with&#xD;
      hepatocellular carcinoma not amenable to other therapies will be explored. Besides, the&#xD;
      effect on the replication of the virus will be analysed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response by Response Evaluation Criteria In Solid Tumors (RECIST)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Hepatitis C Virus (HCV) viral load</measure>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hepatitis C Virus Chronic Infection</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CP 675,206</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unequivocal diagnosis of HCC&#xD;
&#xD;
          -  unresectable disease not amenable to locoregional treatment.&#xD;
&#xD;
          -  a 4-week washout period after sorafenib or any other systemic agent&#xD;
&#xD;
          -  a 2-month washout period after internal or external radiation&#xD;
&#xD;
          -  HCV chronic infection&#xD;
&#xD;
          -  Child-Pugh stage A or B&#xD;
&#xD;
          -  Measurable disease according to RECIST criteria&#xD;
&#xD;
          -  ECOG &lt; 2&#xD;
&#xD;
          -  expected survival &gt; 3 months&#xD;
&#xD;
          -  Adequate liver, renal and blood functions&#xD;
&#xD;
          -  ability to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous treatment with an anti-CTL-4 agent&#xD;
&#xD;
          -  serious infections or disease compromising general health status&#xD;
&#xD;
          -  autoimmune disease that requires therapy&#xD;
&#xD;
          -  treatment with immunosuppressors&#xD;
&#xD;
          -  treatment with investigational agents&#xD;
&#xD;
          -  other neoplasms except skin and bladder superficial tumors&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  SNC metastasis&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  relevant heart disease (NYHA class III or IV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesús Prieto-Valtuena, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>November 3, 2009</study_first_submitted>
  <study_first_submitted_qc>November 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2009</study_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

